MDX 1342

N/A

Report date: 2022/07/04 19:38:02

Base Information

Drug NameMDX 1342
Drug Alias NameMDX-1342
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionB-lymphocyte antigen CD19 inhibitors
TargetsB-lymphocyte antigen CD19
Therapy Area/IndicationsArthritis, RheumatoidLeukemia, Lymphocytic, Chronic, B-Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesUkraineHungary +[5] 
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesMedarex Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesBristol Myers Squibb Srlcompany
Active IndicationsN/A
Inactive IndicationsArthritis, RheumatoidLeukemia, Lymphocytic, Chronic, B-Cell

Other Information

ATC CodeN/A
Related LinksN/A